|
|
|
|
|
|
Sponsored by: |
Hospices Civils de Lyon |
Information provided by: | Hospices Civils de Lyon |
ClinicalTrials.gov Identifier: | NCT00133887 |
In a population of kidney transplant recipients having developed a first squamous cell carcinoma, the aim of the study is to assess the incidence of subsequent skin cancers over 2 years in patients who are switched to rapamycin as compared to patients who are maintained under calcineurin inhibitors.
Condition | Intervention | Phase |
Skin Cancer Kidney Transplantation |
Drug: rapamycin Drug: ciclosporine Drug: tacrolimus |
Phase III |
MedlinePlus related topics: | Cancer Kidney Transplantation Skin Cancer |
Drug Information available for: | Tacrolimus Sirolimus Tacrolimus anhydrous |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-Label Study of Rapamycin vs Calcineurin Inhibitors |
Estimated Enrollment: | 120 |
Study Start Date: | April 2004 |
Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
patients receiving Rapamycin
|
Drug: rapamycin
3 to 5 mg/day
|
2: Active Comparator
patients receiving anticalcineurin treatment
|
Drug: ciclosporine
Blood residual level < or = to 125 ng/ml
Drug: tacrolimus
Blood residual level < or = to 8 ng/ml
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sylvie EUVRARD, MD | 33 472 110 ext 322 | sylvie.euvrard@chu-lyon.fr |
France | |||||
Hôpital Edouard Herriot - Service de Dermatologie | Recruiting | ||||
LYON, France, 69003 | |||||
Contact: Sylvie EUVRARD, MD 33 472 110 ext 322 sylvie.euvrard@chu-lyon.fr | |||||
Principal Investigator: Sylvie EUVRARD, MD |
Hospices Civils de Lyon |
Principal Investigator: | Sylvie EUVRARD, MD | Hospices Civils de Lyon |
Responsible Party: | Hospices Civils de Lyon ( Sylvie EUVRARD ) |
Study ID Numbers: | 2003.333 |
First Received: | August 23, 2005 |
Last Updated: | June 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00133887 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|